Cargando…
Efficacy and safety of a flexible extended regimen of ethinylestradiol/drospirenone for the treatment of dysmenorrhea: a multicenter, randomized, open-label, active-controlled study
BACKGROUND: Dysmenorrhea is a common condition in women, which is characterized by menstrual pain. Low-dose estrogen/progestin combined oral contraceptives have been shown to reduce the severity of dysmenorrhea symptoms, and a 28-day cyclic regimen of ethinylestradiol/drospirenone (28d regimen) is a...
Autores principales: | Momoeda, Mikio, Kondo, Masami, Elliesen, Joerg, Yasuda, Masanobu, Yamamoto, Shigetomo, Harada, Tasuku |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422539/ https://www.ncbi.nlm.nih.gov/pubmed/28496369 http://dx.doi.org/10.2147/IJWH.S134576 |
Ejemplares similares
-
Quality of Life in Japanese Patients with Dysmenorrhea Treated with Ethinylestradiol 20 μg/Drospirenone 3 mg in a Real-World Setting: An Observational Study
por: Momoeda, Mikio, et al.
Publicado: (2020) -
Efficacy of cyclic and extended regimens of ethinylestradiol 0.02 mg ‐levonorgestrel 0.09 mg for dysmenorrhea: A placebo‐controlled, double‐blind, randomized trial
por: Harada, Tasuku, et al.
Publicado: (2021) -
Burden of Menstrual Pain Measured by Heatmap Visualization of Daily Patient-Reported Data in Japanese Patients Treated with Ethinylestradiol/Drospirenone: A Randomized Controlled Study
por: Momoeda, Mikio, et al.
Publicado: (2020) -
Contraceptive efficacy and tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study
por: Klipping, Christine, et al.
Publicado: (2012) -
Efficacy of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen in women with moderate-to-severe primary dysmenorrhoea: an open-label, multicentre, randomised, controlled study
por: Strowitzki, Thomas, et al.
Publicado: (2012)